These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 12684413

  • 1. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
    Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Reich R.
    Clin Cancer Res; 2003 Apr; 9(4):1412-9. PubMed ID: 12684413
    [Abstract] [Full Text] [Related]

  • 2. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
    Davidson B, Reich R, Goldberg I, Gotlieb WH, Kopolovic J, Berner A, Ben-Baruch G, Bryne M, Nesland JM.
    Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247
    [Abstract] [Full Text] [Related]

  • 3. Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma.
    Goldberg I, Davidson B, Reich R, Gotlieb WH, Ben-Baruch G, Bryne M, Berner A, Nesland JM, Kopolovic J.
    Clin Cancer Res; 2001 Dec; 7(12):4073-9. PubMed ID: 11751504
    [Abstract] [Full Text] [Related]

  • 4. Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study.
    Davidson B, Gotlieb WH, Ben-Baruch G, Kopolovic J, Goldberg I, Nesland JM, Berner A, Bjåmer A, Bryne M.
    Gynecol Oncol; 2000 Apr; 77(1):35-43. PubMed ID: 10739688
    [Abstract] [Full Text] [Related]

  • 5. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML.
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [Abstract] [Full Text] [Related]

  • 6. Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
    Konstantinovsky S, Nielsen S, Vyberg M, Kvalheim G, Nesland JM, Reich R, Davidson B.
    Breast Cancer Res Treat; 2005 Nov; 94(1):71-80. PubMed ID: 16142438
    [Abstract] [Full Text] [Related]

  • 7. E-Cadherin complex protein expression and survival in ovarian carcinoma.
    Davidson B, Gotlieb WH, Ben-Baruch G, Nesland JM, Bryne M, Goldberg I, Kopolovic J, Berner A.
    Gynecol Oncol; 2000 Dec; 79(3):362-71. PubMed ID: 11104606
    [Abstract] [Full Text] [Related]

  • 8. Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study.
    Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne M, Ben-Baruch G, Berner A, Reich R.
    Gynecol Oncol; 2001 May; 81(2):166-71. PubMed ID: 11330944
    [Abstract] [Full Text] [Related]

  • 9. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
    Davidson B, Konstantinovsky S, Nielsen S, Dong HP, Berner A, Vyberg M, Reich R.
    Clin Cancer Res; 2004 Nov 01; 10(21):7335-46. PubMed ID: 15534110
    [Abstract] [Full Text] [Related]

  • 10. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
    Gorovetz M, Baekelandt M, Berner A, Trope' CG, Davidson B, Reich R.
    Gynecol Oncol; 2006 Dec 01; 103(3):831-40. PubMed ID: 16919315
    [Abstract] [Full Text] [Related]

  • 11. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B, Lazarovici P, Ezersky A, Nesland JM, Berner A, Risberg B, Tropé CG, Kristensen GB, Goscinski M, van de Putte G, Reich R.
    Clin Cancer Res; 2001 Nov 01; 7(11):3457-64. PubMed ID: 11705863
    [Abstract] [Full Text] [Related]

  • 12. Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival.
    Davidson B, Hadar R, Stavnes HT, Trope' CG, Reich R.
    Hum Pathol; 2009 May 01; 40(5):705-13. PubMed ID: 19157507
    [Abstract] [Full Text] [Related]

  • 13. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM.
    Clin Cancer Res; 2004 Nov 15; 10(22):7621-8. PubMed ID: 15569994
    [Abstract] [Full Text] [Related]

  • 14. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL, Mao TL, Chan WY, Huang SC, Lin CT.
    Gynecol Oncol; 2004 Feb 15; 92(2):559-67. PubMed ID: 14766248
    [Abstract] [Full Text] [Related]

  • 15. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
    Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B, Tropé CG, Flørenes VA.
    Clin Cancer Res; 2003 Jun 15; 9(6):2248-59. PubMed ID: 12796393
    [Abstract] [Full Text] [Related]

  • 16. Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
    Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Risberg B, Ben-Baruch G, Reich R.
    Cancer Metastasis Rev; 2003 Mar 15; 22(1):103-15. PubMed ID: 12716042
    [Abstract] [Full Text] [Related]

  • 17. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
    Davidson B, Alejandro E, Flørenes VA, Goderstad JM, Risberg B, Kristensen GB, Trope CG, Kohn EC.
    Cancer; 2004 May 15; 100(10):2139-47. PubMed ID: 15139056
    [Abstract] [Full Text] [Related]

  • 18. Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis.
    Arora S, Kaur J, Sharma C, Mathur M, Bahadur S, Shukla NK, Deo SV, Ralhan R.
    Clin Cancer Res; 2005 Mar 15; 11(6):2272-84. PubMed ID: 15788677
    [Abstract] [Full Text] [Related]

  • 19. Human kallikrein 8 (hK8/TADG-14) expression is associated with an early clinical stage and favorable prognosis in ovarian cancer.
    Shigemasa K, Tian X, Gu L, Tanimoto H, Underwood LJ, O'Brien TJ, Ohama K.
    Oncol Rep; 2004 Jun 15; 11(6):1153-9. PubMed ID: 15138549
    [Abstract] [Full Text] [Related]

  • 20. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
    Konecny G, Untch M, Pihan A, Kimmig R, Gropp M, Stieber P, Hepp H, Slamon D, Pegram M.
    Clin Cancer Res; 2001 Jun 15; 7(6):1743-9. PubMed ID: 11410515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.